GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (NAS:MRNA) » Definitions » Long-Term Capital Lease Obligation
中文

Moderna (Moderna) Long-Term Capital Lease Obligation : $1,218 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Moderna Long-Term Capital Lease Obligation?

Moderna's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,218 Mil.

Moderna's quarterly Long-Term Capital Lease Obligation increased from Jun. 2023 ($947 Mil) to Sep. 2023 ($1,272 Mil) but then declined from Sep. 2023 ($1,272 Mil) to Dec. 2023 ($1,218 Mil).

Moderna's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($705 Mil) to Dec. 2022 ($1,004 Mil) and increased from Dec. 2022 ($1,004 Mil) to Dec. 2023 ($1,218 Mil).


Moderna Long-Term Capital Lease Obligation Historical Data

The historical data trend for Moderna's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Long-Term Capital Lease Obligation Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial 132.36 207.00 705.00 1,004.00 1,218.00

Moderna Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,004.00 927.00 947.00 1,272.00 1,218.00

Moderna  (NAS:MRNA) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Moderna Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Moderna's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna (Moderna) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (NAS:MRNA) » Definitions » Long-Term Capital Lease Obligation
Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Executives
Stephen Hoge officer: President C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James M Mock officer: Chief Financial Officer 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Shannon Thyme Klinger officer: Chief Legal Officer 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Noubar Afeyan director, 10 percent owner C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arpa Garay officer: Chief Commercial Officer 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Stephane Bancel director, officer: Chief Executive Officer 320 BENT STREET, CAMBRIDGE MA 02141
Juan Andres officer: See Remarks C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paul Burton officer: Chief Medical Officer 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
David W Meline officer: Chief Financial Officer 3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Jorge M Gomez officer: See Remarks C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Sagan director AKAMAI TECHNOLOGIES INC, 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Tal Zvi Zaks officer: Chief Medical Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Lori M. Henderson officer: General Counsel and Secretary MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Le Goff Corinne officer: Chief Commercial Officer 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115

Moderna (Moderna) Headlines

From GuruFocus

Moderna Inc to Host ESG Day Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Moderna Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Moderna Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-23-2024

Moderna Inc R&D Day Transcript

By GuruFocus Research 01-23-2024

Moderna Inc Vaccines Day Transcript

By GuruFocus Research 01-23-2024

Moderna Inc Clinical Data Call Transcript

By GuruFocus Research 01-23-2024

Moderna Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Moderna Inc ASCO Call Transcript

By GuruFocus Research 01-23-2024